VIR

8.3905.41%
VL

Vicki L. Sato

Independent Chairman

Dr. Vicki L. Sato, Ph.D. is Independent Director of ClavystBio Pte Ltd. Dr. Sato is the Director of Encoded Therapeutics, Inc. since 2023 and Aera Therapeutics Inc. She serves as an Advisor of Ginger.io, Inc. Dr. Sato has served as Director at Allogene Therapeutics, Inc. since July 2021 and serves as its Independent Director. Dr. Sato is a part of the Atlas Venture LLP's life sciences group. She serves as a Business Advisor at other enterprises in the biotechnology and pharmaceutical industries. She serves as Venture Partner at Arch Venture Partners, L.P. She focuses on Biotechnology and Pharmaceuticals. She served as Advisor at Atlas Venture L.P. She served as the President of Vertex Pharmaceuticals Incorporated from December 2000 to May 11, 2005. Dr. Sato serves as Member of Advisory Board of Vaxess Technologies, Inc. Dr. Sato joined Vertex Pharmaceuticals Incorporated in September 1992 as Vice President of Research and Chief Scientific Officer from 1992 to 2000 and served as its Senior Vice President of Research and Development in September 1994. Previously, she also served as the Vice President of Research and a Member of the Scientific Board of Biogen, Inc. from 1984 to 1992. As the Research Head at Biogen, she directed research programs in the fields of inflammation, immunology, thrombosis, AIDS therapy and cardiovascular therapy from early research into advanced product development and participated in the executive management of the company. She was responsible for research and development, business and corporate development, commercial operations, legal and finance at Vertex Pharmaceuticals Incorporated. She served as a Chair of the Scientific Advisory Board at Vertex Pharmaceuticals Incorporated from 1992 to December 2000 and also served as its Member of Scientific Advisory Board. She had been the Independent Chairperson at Denali Therapeutics Inc. since August 2016 until June 3, 2025 and had been its Independent Director since April 2015 until June 3, 2025. Dr. Sato retired in 2005 from Vertex Pharmaceuticals, where she served as President since 2000. She was a Professor of Harvard Business School of Vir Biotechnology, Inc. She was the Independent Chairman of Vir Biotechnology, Inc. since December 2016. She serves as Chairman of the board of directors at Vir Biotechnology and as a business advisor to enterprises in the biotechnology and pharmaceutical industries. Dr. Sato served as an Independent Director of BorgWarner Inc. since February 12, 2014 until April 2021. She had been a Director of Akouos, Inc. since February 2020 until December 1, 2022. Dr. Sato serves as a Member of the Advisory Board of BioVentures Investors, LLC. She served as an Independent Director of PerkinElmer, Inc. since 2001 until April 25, 2017. She serves as a Director of Prize4Life and the Broad Institute (Board of Scientific Counselors). She serves as a Director of Avila Therapeutics, Inc. Celgene Avilomics Research, Inc. and served as Director at Nimbus Therapeutics, Inc. She had been an Independent Director of Bristol-Myers Squibb Company since July 11, 2006 until May 4, 2021 and had been its Lead Independent Director since May 02, 2017 until May 4, 2021. She serves as a Director of Bristol Myers Squibb Company and Bristol-Myers Squibb Farmacêutica Portuguesa, SA. She served as a Director of Proclara Biosciences, Inc. (formerly NeuroPhage Pharmaceuticals, Inc.) since 2008. She was Director of Syros Pharmaceuticals, Inc. since August 2013 until December 19, 2019. She served as an Independent Director of Infinity Pharmaceuticals, Inc. from September 2006 to June 17, 2009 and also served as its Member of scientific Advisory Board until November 2006 and Lead Outside Director. She served as an Independent Director of Galapagos NV from April 26, 2011 to December 31, 2014. She served as a Member of Advisory Board at Signals Analytics (also known as Signals Intelligence Group Ltd.) from April 2015 to February 2, 2017. In 2021 she was appointed to President Joseph Biden's Council of Advisors in Science and Technology (PCAST).She served as a Director of Alnylam Pharmaceuticals Inc. from December 8, 2005 to April 2011. Dr. Sato served on the Board of Tutors of the Department of Biochemistry and Molecular Biology at Harvard University. She was a Professor of the Practice in the Department of Molecular and Cell Biology, Harvard University from July 2005 until October 2015. Dr. Sato served as Professor of Management Practice at Harvard Business School from September 2006 until her retirement in July 2017. At Harvard, she was Founding Faculty Chair of the Blavatnik Fellowship in Life Science Entrepreneurship program. Dr. Sato also serves as a Trustee of Jose Mateo's Ballet Theatre, Chair of the Overseers of the Isabella Stewart Gardner Museum and an Advisor to the Accelerated Cure Project. She serves as Director at PerkinElmer LAS (Germany) GmbH. Previously, she served as a board member for several U.S. publicly traded companies biotech and biopharma companies. Dr. Sato serves as a Trustee of the Boston Museum of Science. She was appointed co-chair of the Advisory Council of LifeSci: NYC, a public service group that advises New York City on matters of life science competitiveness. She also served as both an Assistant and an Associate Professor in the Department of Biology at Harvard University from 1976 to 1983. She is the author of numerous professional publications and holds several issued or pending patents. Following postdoctoral work at both the University of California Berkeley and Stanford Medical Center, Dr. Sato was appointed to the faculty of Harvard University, where she was an assistant and associate professor of biology. Dr. Sato received her A.B. in Biology from Radcliffe College and her A.M. and Ph.D. in Biology from Harvard University. She conducted her postdoctoral work at both the University of California, Berkeley and Stanford Medical Center.

Positions